Hye-Nam Son

Title: Hye-Nam Son: Innovator in Monoclonal Antibody Development

Introduction

Hye-Nam Son is a prominent inventor based in Seoul, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work focuses on enhancing the specificity and affinity of antibodies for better diagnostic applications.

Latest Patents

Hye-Nam Son holds a patent for a monoclonal antibody specifically binding to CCSP-2. The patent, titled "Monoclonal antibody specifically binding to CCSP-2 and use thereof," describes an innovative monoclonal antibody that targets the EGF2 domain of colon cancer secreted protein-2 (CCSP-2). This invention demonstrates significantly increased affinity compared to existing peptides and improved specificity over current antibodies targeting CCSP-2. The potential for accurate diagnosis through specific detection of CCSP-2 at the protein level is a key highlight of this invention. He has 1 patent to his name.

Career Highlights

Throughout his career, Hye-Nam Son has worked with various organizations, contributing to advancements in medical research and biotechnology. His experience includes positions at Edisbiotech Co., Ltd. and the University of Ulsan Foundation for Industry Cooperation. These roles have allowed him to collaborate with other experts in the field and further his research endeavors.

Collaborations

Hye-Nam Son has collaborated with notable colleagues, including Hyori Kim and A-Neum Lee. Their combined expertise has contributed to the success of various projects and research initiatives.

Conclusion

Hye-Nam Son's innovative work in monoclonal antibody development positions him as a key figure in biotechnology. His contributions have the potential to significantly impact the accuracy of cancer diagnostics in the future.